drugset / Trial / NCT02827643
Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz
RandomizedSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to determine whether calcium and vitamin D supplement can attenuate bone loss in HIV-infected-patients in Thailand who receive Tenofovir disoproxil fumarate.
Timeline
- Start
- 2016-06
- Primary completion
- 2017-03
- Completion
- 2017-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Calcium carbonate | Other / unclassified | 1250 mg | — |
| Comparator | Ergocalciferol | Small molecule | 20000 iu | — |
| Comparator | Efavirenz | Other / unclassified | — | — |
| Comparator | Lamivudine | Other / unclassified | — | — |
| Comparator | Tenofovir disoproxil fumarate | Small molecule | — | — |
| Comparator | emtricitabine | Other / unclassified | — | — |